

Lung Cancer KOL Search

Engagement: Advisory board

Objective: Physicians focusing on lung carcinoma

Client: Sample client

Brand: Sample brand

Profiles: 9

Prepared: 2026-10-06

How to read this document

Profile: A concise overview of each expert's experience, research and clinical focus

Project fit: The next slide breaks down the expert's score against your brief

Activity counts: Publication and congress totals count distinct records found in this profile, not complete career totals. Congress activity includes conference contributions, talks, webinars and interviews

Sources: Bracketed numbers open the sources. Full references are listed at the end

Candidate summary

Adrian K. Vasquez: MD	Role: Assistant Professor, NYU Grossman School of Medicine	Clinical focus: Thoracic Oncology; Medical Oncology	Project fit: 100/100
Nadia A. Brenner: MD	Role: Associate Professor of Oncology, Johns Hopkins School of Medicine	Clinical focus: Medical Oncology	Project fit: 100/100
Marta C. Delaney: MD	Role: Assistant Professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital	Clinical focus: Thoracic malignancies; Non-small cell lung cancer; Small cell lung cancer; Pulmonary carcinoid tumors; Thymic malignancies	Project fit: 100/100
Irene S. Halvorsen: MD, MPH	Role: Associate Professor, Clinical Research Division, Fred Hutch, Fred Hutch	Clinical focus: Head and neck cancers; Thoracic cancers; Medical Oncology	Project fit: 97.5/100
Roy A. Castellan: MD, MS	Role: Endowed Chair, George C. and Margaret M. Hillenbrand Endowed Chair, MUSC	Clinical focus: Interventional pulmonary medicine	Project fit: 97.5/100
Dorian Petrescu: MD	Role: Professor of Medicine, UChicago Medicine Faculty Physicians	Clinical focus: Interventional Pulmonology	Project fit: 69.2/100
Edmund M. Rusk: MD, PhD	Role: Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center	Clinical focus: Thoracic cancers; Lung cancer	Project fit: 41.2/100
Arun S. Mehta: MD, MS	Role: Associate Professor of Medicine, UChicago Medicine Faculty Physicians	Clinical focus: Critical Care Medicine; Interventional Pulmonology	Project fit: 39.6/100

Candidate summary - continued

Colin J. Wexford: MD, PhD	Role: Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center	Clinical focus: Clinical trials	Project fit: 39.6/100
----------------------------------	--	--	------------------------------

Adrian K. Vasquez, MD

Assistant Professor

NYU Grossman School of Medicine | New York, NY

PROJECT FIT

100 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Adrian K. Vasquez is a medical oncologist specializing in caring for people with lung cancers, including non-small cell lung cancer and small cell lung cancer [\[1\]](#)



Relevant experience

- Leads High Reliability Organization Initiatives at Perlmutter Cancer Center [\[1\]](#)
- Has shared expertise through 1 presentation and 3 hosted discussions, covering medical Oncology [\[5\]](#) [\[7\]](#) [\[9\]](#) [\[15\]](#)
- Has contributed to 2 congress abstracts [\[10\]](#) [\[4\]](#)



Research

- Publications found: 7 [\[13\]](#) [\[8\]](#) [\[11\]](#)



Clinical focus

- Thoracic Oncology [\[1\]](#)
- Medical Oncology [\[1\]](#)



Professional societies

- American Society of Clinical Oncology (ASCO) [\[14\]](#)



Congress activity

- Total: 8 (4 congress records + 4 talks/interviews) [\[10\]](#) [\[5\]](#) [\[15\]](#)

Sources [\[1\]](#) nyulangone.org [\[4\]](#) 2025 ASCO Annual... [\[5\]](#) IASLC 2026 World... [\[7\]](#) Breaking Down... [\[8\]](#) Pan-tumor activity... [\[9\]](#) Experts Highlight...

Full references in appendix

Adrian K. Vasquez: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

100 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[2\]](#) [\[1\]](#) [\[4\]](#)

35 / 35 points

35% of total

Clinical experience

5 clinical or research records matched your brief [\[2\]](#) [\[1\]](#) [\[1\]](#)

25 / 25 points

25% of total

Supporting information

12 matched records backed by 10 linked sources [\[2\]](#) [\[1\]](#) [\[4\]](#)

20 / 20 points

20% of total

Speaking and professional activity

6 professional activities matched your brief, such as talks or conference contributions [\[4\]](#) [\[5\]](#) [\[6\]](#)

20 / 20 points

20% of total

Adrian K. Vasquez: Supporting evidence

Congress / speaking: Lung Cancer—Non-Small Cell Metastatic (poster session) · 2026 ASCO Annual Meeting · Co-author of posters: abstract 8613 and 8614 (COPERNICUS, SC amivantamab, EGFR-mutated NSCLC) and 8616 (Beamion LUNG-1 PRO, treatment-naive HER2-mutant NSCLC) · Abstract co-author (not a speaker role) [\[10\]](#)

Congress / speaking: Reported HER2-mutant NSCLC data from the congress (COR2ED conference update) · IASLC 2026 World Conference on Lung Cancer (WCLC 2026) · Attendee; conference update reporter (not a programme speaker role) [\[5\]](#)

Congress / speaking: Understanding the Importance of Biomarker Testing in Lung Cancer (CURE on-site interview) · IASLC 2025 World Conference on Lung Cancer (WCLC 2025) · Biomarker testing in lung cancer; on-site interview with patient advocate Terri Conneran · Interviewer (CURE editor-in-chief), on-site at congress [\[15\]](#)

Congress / speaking: Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): Results from the Beamion LUNG-1 trial · 2025 ASCO Annual Meeting · Abstract 8620 (J Clin Oncol 43:16_suppl): Beamion LUNG-1 zongertinib PRO results, HER2-mutant NSCLC · Abstract first author [\[4\]](#)

Congress / speaking: LUNG CONNECT: How are new data shaping the landscape in HER2-mutant NSCLC? Insights from WCLC 2026 · HER2-mutant non-small cell lung cancer (NSCLC) data update from WCLC 2026 · Expert presenter [\[5\]](#)

Congress / speaking: Highlights from the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting · 2026-08-24 · Lung cancer highlights from ASCO 2026 Annual Meeting (patient education workshop) · Facilitator [\[6\]](#)

Congress / speaking: Breaking Down Advancements in Prostate Cancer Care · 2025-11-14 · Post-2025 ESMO Congress discussion of prostate cancer advances with Dr. Chandler Park · Host/interviewer (video) [\[7\]](#)

Adrian K. Vasquez: Supporting evidence - continued

Congress / speaking: Experts Highlight Notable Advances in Colorectal Cancer at 2025 ESMO · 2025-11-13 · Colorectal cancer data presented at 2025 European Society for Medical Oncology (ESMO) Congress, with Dr. Marcus Hale · Host/interviewer (video) [\[9\]](#)

Professional profile [\[1\]](#)

Nadia A. Brenner, MD

Associate Professor of Oncology

Johns Hopkins School of Medicine | Baltimore, MD

PROJECT FIT

100 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Expertise in Oncogene Mutated NSCLC and Non-small Cell Lung Cancer (NSCLC) is relevant to this advisory board brief [\[17\]](#)



Relevant experience

- Has shared expertise through 1 presentation, 1 chaired session and 1 interview [\[19\]](#) [\[20\]](#) [\[26\]](#)
- Has coauthored 2 congress abstracts, covering immunotherapy [\[28\]](#) [\[30\]](#)
- Scheduled to present at 1 event [\[23\]](#)



Research

- Publications found: 7 [\[17\]](#) [\[25\]](#) [\[18\]](#)
- Non-small Cell Lung Cancer (NSCLC); Oncogene Mutated NSCLC; Immunotherapy; Tumor Metabolism [\[17\]](#)



Clinical focus

- Medical Oncology [\[17\]](#)



Professional societies

- Society for Immunotherapy in Cancer (SITC) [\[17\]](#)
- American Society of Clinical Oncology (ASCO) [\[17\]](#)



Congress activity

- Total: 8 (4 congress records + 4 talks/interviews) [\[28\]](#) [\[30\]](#) [\[27\]](#)

Sources [\[17\]](#) [profiles.hopkinsmedic...](#) [\[18\]](#) [Osimertinib plus...](#) [\[19\]](#) [2024 KRAS Kickers...](#) [\[20\]](#) [IASLC | ASCO 2025...](#) [\[23\]](#) [2026 UVA Medical...](#) [\[25\]](#) [Educational...](#)

Full references in appendix

Nadia A. Brenner: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

100 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[16\]](#) [\[17\]](#) [\[18\]](#)

35 / 35 points

35% of total

Clinical experience

5 clinical or research records matched your brief [\[16\]](#) [\[17\]](#) [\[18\]](#)

25 / 25 points

25% of total

Supporting information

12 matched records backed by 10 linked sources [\[16\]](#) [\[17\]](#) [\[18\]](#)

20 / 20 points

20% of total

Speaking and professional activity

5 professional activities matched your brief, such as talks or conference contributions [\[19\]](#) [\[20\]](#) [\[26\]](#)

20 / 20 points

20% of total

Nadia A. Brenner: Supporting evidence

Congress / speaking: Poster Presentations - Proffered Abstracts · AACR Annual Meeting 2026 · Abstract: Clinical utility of landmark ctDNA molecular response as an early indicator of immunotherapy outcomes in lung cancer. (Cancer Res 2026;86(7_Supplement):110) · Abstract co-author (not a speaking role) [\[28\]](#)

Congress / speaking: Abstract: Prophylactic peptide vaccine targeting resistance mutations in advanced ALK-positive lung cancer: Primary analysis from the ARCHER trial. (J Clin Oncol 44(16_suppl):8517) · 2026 ASCO Annual Meeting · Abstract co-author (not a speaking role) [\[30\]](#)

Congress / speaking: Scheduled future event (lung cancer); listed among 2026 NACLC Co-Chairs · IASLC North America Conference on Lung Cancer 2026 (NACLC 2026) · Conference co-chair (scheduled) [\[27\]](#)

Congress / speaking: Conference organisation (thoracic oncology / lung cancer) · IASLC | ASCO 2025 North America Conference on Lung Cancer (NACLC 2025) · Conference chair (one of four 2025 conference chairs) [\[20\]](#)

Congress / speaking: 2024 KRAS Kickers Hope Filled Summit · Talk on KRAS peptide vaccine clinical trial portfolio (KRAS-mutated cancers incl. NSCLC), with audience Q&A · Speaker [\[19\]](#)

Congress / speaking: Mastering Fellowship Interview Season: What Programs Value and How Applicants Can Stand Out · X Space discussion on fellowship interviews (medical education) · Featured guest (hosted by Dr. Shreyas Kalantri) [\[22\]](#)

Congress / speaking: Preview: IASLC | ASCO 2025 North American Conference on Lung Cancer (podcast) · Podcast previewing NACLC 2025 (lung cancer) · Podcast guest [\[26\]](#)

Congress / speaking: 2026 UVA Medical Oncology Update · 2026-11-06 · Scheduled future event; keynote in Thoracic Oncology session · Keynote speaker (scheduled) [\[23\]](#)

Professional profile [\[17\]](#)

Marta C. Delaney, MD

Assistant Professor of Oncology

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital | Washington, DC

PROJECT FIT

100 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Expertise in EGFR lung cancer and small cell lung cancer is relevant to this advisory board brief [\[31\]](#)



Relevant experience

- Has shared expertise through 1 presentation, 1 panel discussion and 2 education programs, covering small cell lung cancer and non-small cell lung cancer [\[41\]](#) [\[32\]](#) [\[37\]](#) [\[36\]](#)
- Has coauthored 1 congress abstract [\[33\]](#)



Research

- Publications found: 7 [\[29\]](#) [\[39\]](#) [\[38\]](#)
- EGFR lung cancer; Clinical trials in resectable lung cancer; Early stage lung cancer; HER2; Immunotherapy; Novel targeted therapies; EGFR- and HER2-mutated lung cancers [\[31\]](#)



Clinical focus

- Non-small cell lung cancer [\[31\]](#)
- Small cell lung cancer [\[31\]](#)
- Thoracic malignancies [\[31\]](#)



Professional societies

- American Society of Clinical Oncology (ASCO) [\[31\]](#)
- International Association for the Study of Lung Cancer (IASLC) [\[31\]](#)



Congress activity

- Total: 6 (2 congress records + 4 talks/interviews) [\[33\]](#) [\[41\]](#) [\[37\]](#)

Sources [\[29\]](#) Serial Plasma... [\[31\]](#) profiles.hopkinsmedic... [\[32\]](#) Comparing... [\[33\]](#) 2026 ASCO Annual... [\[36\]](#) Immunotherapy in... [\[37\]](#) Unveiling the Latest...

Full references in appendix

Marta C. Delaney: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

100 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[32\]](#) [\[33\]](#) [\[34\]](#)

35 / 35 points

35% of total

Clinical experience

6 clinical or research records matched your brief [\[34\]](#) [\[35\]](#) [\[29\]](#)

25 / 25 points

25% of total

Supporting information

18 matched records backed by 12 linked sources [\[32\]](#) [\[33\]](#) [\[34\]](#)

20 / 20 points

20% of total

Speaking and professional activity

9 professional activities matched your brief, such as talks or conference contributions [\[32\]](#) [\[33\]](#) [\[36\]](#)

20 / 20 points

20% of total

Marta C. Delaney: Supporting evidence

Congress / speaking: Primary analysis from the ARCHER trial (ctDNA, lung cancer) · 2026 ASCO Annual Meeting · Listed among top lung cancer abstracts at ASCO 2026 · Abstract co-author (not established as speaker) [\[33\]](#)

Congress / speaking: EGFR-Mutated NSCLC: Subcutaneous Amivantamab Plus Lazertinib · IASLC 2025 World Conference on Lung Cancer (WCLC 2025) · Findings from cohort 5 of phase II PALOMA-2 (SC amivantamab q4w + lazertinib, EGFR-mutated NSCLC); ASCO Post video · Presenter of trial findings (video interview) [\[41\]](#)

Congress / speaking: Unveiling the Latest Updates in EGFR-Mutated Advanced NSCLC · CME activity on managing EGFR-mutated advanced NSCLC · Author/faculty [\[37\]](#)

Congress / speaking: Future Directions Beyond Osimertinib in EGFR-Mutant NSCLC · 2026-09-03 · EGFR-mutant non-small cell lung cancer (NSCLC) treatment beyond osimertinib; video discussion series · Faculty discussant (with Mark A. Socinski, MD) [\[40\]](#)

Congress / speaking: Comparing Osimertinib-Based Frontline Combination Regimens in EGFR-Mutant NSCLC · 2026-08-13 · Frontline osimertinib-based combinations in EGFR-mutant NSCLC; video discussion series · Faculty discussant [\[32\]](#)

Congress / speaking: Immunotherapy in Action: Multidisciplinary Strategies to Improve Care in Advanced/Metastatic NSCLC · 2025-12-30 · Immunotherapy in advanced/metastatic NSCLC; online activity (also listed Dec 9, 2025) · Faculty [\[36\]](#)

Professional profile [\[31\]](#)

Irene S. Halvorsen, MD, MPH

Associate Professor, Clinical Research Division, Fred Hutch

Fred Hutch | Seattle, WA

PROJECT FIT

97.5 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Expertise in Immunotherapy in lung cancer and Understanding the mechanisms of primary and secondary resistance to immunotherapy in lung cancer is relevant to this advisory board brief [\[45\]](#)



Relevant experience

- Leads clinical research on targeted therapies and immunotherapies and how some cancers resist these forms of treatment [\[45\]](#)
- Has shared expertise through 1 presentation, 1 moderated discussion and 1 interview [\[49\]](#) [\[53\]](#) [\[55\]](#)
- Scheduled to present at 2 events [\[52\]](#) [\[48\]](#)



Research

- Publications found: 6 [\[44\]](#) [\[47\]](#) [\[43\]](#)



Clinical focus

- Head and neck cancers [\[45\]](#)
- Thoracic cancers [\[45\]](#)
- Medical Oncology [\[45\]](#)



Professional societies

- No society affiliations found



Congress activity

- Total: 7 (3 congress records + 4 talks/interviews) [\[42\]](#) [\[49\]](#) [\[53\]](#)

Sources [\[42\]](#) 2025 American... [\[43\]](#) First-Line... [\[44\]](#) Mature Outcomes and... [\[45\]](#) fredhutch.org [\[47\]](#) BLU-451, a... [\[48\]](#) A New Era of...

Full references in appendix

Irene S. Halvorsen: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

97.5 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[42\]](#) [\[43\]](#) [\[44\]](#)

35 / 35 points

35% of total

Clinical experience

3 clinical or research records matched your brief [\[43\]](#) [\[44\]](#) [\[51\]](#)

22.5 / 25 points

25% of total

Supporting information

12 matched records backed by 10 linked sources [\[42\]](#) [\[43\]](#) [\[44\]](#)

20 / 20 points

20% of total

Speaking and professional activity

6 professional activities matched your brief, such as talks or conference contributions [\[42\]](#) [\[46\]](#) [\[48\]](#)

20 / 20 points

20% of total

Irene S. Halvorsen: Supporting evidence

Congress / speaking: Lung Cancer—Non-Small Cell Metastatic · 2025 American Society of Clinical Oncology (ASCO) Annual Meeting · author [\[42\]](#)

Congress / speaking: Which treatment regimen is better for patients with EGFR-mutated lung cancer: the one studied in the MARIPOSA clinical trial or that of the FLAURA2 study · Seattle Lung Cancer Conference · 2025 · presenter [\[49\]](#)

Congress / speaking: Metastatic NSCLC with Genomic Alterations · Masters in Thoracic Oncology Summit · 2024 · Session: Metastatic NSCLC with Genomic Alterations · moderator [\[53\]](#)

Congress / speaking: 2026 Lung Cancer Patient Empowerment Webinar · 2026-11-14 · Scheduled future event (2026-11-14): Welcome remarks; Lung Cancer 101 · speaker [\[52\]](#)

Congress / speaking: Winter Lung 2026 · 2026-01-24 · Oligometastatic NSCLC: Challenges, Dilemmas, and Clinical Decisions [\[46\]](#)

Congress / speaking: A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs · 2025-09-07 · Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum · faculty presenter (as listed on agenda) [\[48\]](#)

Congress / speaking: Dr Halvorsen on the Clinical Utility of Zongertinib in Previously Treated HER2-Mutant NSCLC · 2024-11-06 · Clinical utility of zongertinib in previously treated HER2-mutant NSCLC · interviewee [\[55\]](#)

Professional profile [\[45\]](#)

Roy A. Castellan, MD, MS

Endowed Chair, George C. and Margaret M. Hillenbrand Endowed Chair

MUSC | Edmondton, SC

PROJECT FIT

97.5 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Expertise in lung cancer and health policy implications of a mass lung cancer screening program is relevant to this advisory board brief [\[56\]](#)



Relevant experience

- Has shared expertise through 1 presentation, 1 hosted discussion, 1 chaired session and 2 interviews, covering lung cancer [\[60\]](#) [\[58\]](#) [\[68\]](#) [\[62\]](#)
- Has coauthored 2 congress abstracts [\[65\]](#) [\[57\]](#)



Research

- Publications found: 5 [\[59\]](#) [\[66\]](#) [\[70\]](#)



Clinical focus

- Interventional pulmonary medicine [\[56\]](#)



Professional societies

- American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) [\[64\]](#)
- American College of Chest Physicians (CHEST) [\[69\]](#)



Congress activity

- Total: 7 (4 congress records + 3 talks/interviews) [\[65\]](#) [\[57\]](#) [\[60\]](#)

Roy A. Castellan: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

97.5 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[56\]](#) [\[58\]](#) [\[60\]](#)

35 / 35 points

35% of total

Clinical experience

3 clinical or research records matched your brief [\[63\]](#) [\[67\]](#) [\[70\]](#)

22.5 / 25 points

25% of total

Supporting information

11 matched records backed by 9 linked sources [\[56\]](#) [\[58\]](#) [\[60\]](#)

20 / 20 points

20% of total

Speaking and professional activity

5 professional activities matched your brief, such as talks or conference contributions [\[58\]](#) [\[60\]](#) [\[61\]](#)

20 / 20 points

20% of total

Roy A. Castellan: Supporting evidence

Congress / speaking: (Poster Board #313) Should We Start With PET or Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules: Insights From Monte Carlo Simulations · Biodesix ATS 2026 presentations (ATS 2026 International Conference) · pulmonary nodule risk stratification poster · abstract coauthor (not a speaker) [\[65\]](#)

Congress / speaking: AI: Cracking the Code in Innovations in Lung · Evaluation Of An Artificial Intelligence-Generated Brock Score To Determine Malignancy Risk In Screen Detected Nodules · Abstract in Chest 2025 supplement (doi 10.1016/j.chest.2025.07.2676); author disclosure lists grant/research support · abstract coauthor (not a speaker) [\[57\]](#)

Congress / speaking: President's Symposium · ATS 2024 International Conference - President's Symposium · 50 years of lung cancer screening practices and guidelines · speaker [\[60\]](#)

Congress / speaking: Screening and Early Detection track · IASLC 2024 World Conference on Lung Cancer · International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer · Track Chair [\[68\]](#)

Congress / speaking: CHEST Journal Podcast · Outcomes From More Than 1 Million People Screened for Lung Cancer With Low-Dose CT Imaging · guest [\[62\]](#)

Congress / speaking: Deep Breaths: Updates from CHEST · Understanding Extensive-Stage Small Cell Lung Cancer: Advancements and Ongoing Challenges · host [\[58\]](#)

Congress / speaking: Health Focus · 2026-08-17 · Research regarding advanced lung cancer patients and treatment (systemic treatment rates in metastatic NSCLC) · interviewee [\[61\]](#)

Professional profile [\[56\]](#)

Dorian Petrescu, MD

Professor of Medicine

UChicago Medicine Faculty Physicians | Chicago, IL

PROJECT FIT

69.2 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Expertise in management of patients with lung cancer is relevant to this advisory board brief [\[72\]](#)



Relevant experience

- Has shared expertise through 5 presentations, covering interventional Pulmonology [\[71\]](#) [\[84\]](#) [\[85\]](#) [\[86\]](#)
- Scheduled to present at 2 events [\[80\]](#) [\[78\]](#)



Research

- Publications found: 6 [\[76\]](#) [\[79\]](#) [\[83\]](#)



Clinical focus

- Interventional Pulmonology [\[72\]](#)



Professional societies

- International Association for the Study of Lung Cancer (IASLC) [\[72\]](#)
- American College of Chest Physicians (CHEST) [\[82\]](#)



Congress activity

- Total: 7 (3 congress records + 4 talks/interviews) [\[86\]](#) [\[77\]](#) [\[78\]](#)

Sources [\[71\]](#) Navigating the Path... [\[72\]](#) uchicagomedicine.org [\[73\]](#) American Association... [\[76\]](#) Response to 'A... [\[77\]](#) AABIP 2025 Annual... [\[78\]](#) WABIP Two-Day Global...

Full references in appendix

Dorian Petrescu: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

69.2 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[72\]](#) [\[75\]](#) [\[81\]](#)

35 / 35 points

35% of total

Clinical experience

2 clinical or research records matched your brief [\[75\]](#) [\[81\]](#)

15 / 25 points

25% of total

Supporting information

5 matched records backed by 3 linked sources [\[72\]](#) [\[75\]](#) [\[81\]](#)

12.2 / 20 points

20% of total

Speaking and professional activity

1 professional activity matched your brief, such as talks or conference contributions [\[72\]](#)

7 / 20 points

20% of total

Dorian Petrescu: Supporting evidence

Congress / speaking: AABIP 2026 Annual Conference · Speaker (listed among AABIP 2026 Speakers Included) [\[86\]](#)

Congress / speaking: Interview Skills for Both Parties: Interviewee and Interviewer · AABIP 2025 Annual Conference · Workshop / Ask the Expert session on matching into an interventional pulmonology (IP) fellowship · Speaker (listed as Dr. Tim Petrescu) [\[77\]](#)

Congress / speaking: Virtual two-day global educational meeting; bronchoscopy evolution, robotic bronchoscopy, rigid bronchoscopy; announced as save-the-date (scheduled) in Sep 2025 newsletter · WABIP Two-Day Global Webinar (World Association for Bronchology and Interventional Pulmonology) · Selected speaker (scheduled) [\[78\]](#)

Congress / speaking: Navigating the Path Ahead: Preparing for Life Beyond IP Fellowship (2026) · Session chair; speaker on deep work, time management, skills development and mentorship (Presentation + Interactive Workshop) · Session Chair and Speaker [\[71\]](#)

Congress / speaking: 2025 IP Fellows Advanced Course · Deep Work, Productivity & Time Management (Presentation + Interactive Workshop) · Speaker (with Hans Lee MD) [\[84\]](#)

Congress / speaking: Tips for a Successful IP Training 2025 · Introduction and Welcome; Tips for achieving competency and expertise in interventional pulmonology · Co-host and speaker [\[85\]](#)

Congress / speaking: 4Th Annual State of the Art Lung Nodule Symposium 2025: Current Perspectives & Future Directions · Lung nodule diagnosis (diagnostic yield); 08:20-08:40 talk · Speaker [\[80\]](#)

Professional profile [\[72\]](#)

Edmund M. Rusk, MD, PhD

Thoracic Medical Oncologist

Memorial Sloan Kettering Cancer Center | New York, NY

PROJECT FIT

41.2 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Expertise in Lung cancer and Therapeutic research in lung cancer is relevant to this advisory board brief [\[87\]](#)



Relevant experience

- Experience details unavailable



Research

- Publications found: 0
- Therapeutic research in lung cancer; Including laboratory-based investigations; Early-phase clinical trials; Later-phase studies [\[87\]](#)



Clinical focus

- Lung cancer [\[87\]](#)
- Thoracic cancers [\[87\]](#)



Professional societies

- No society affiliations found



Congress activity

- Activities found: 0

Edmund M. Rusk: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

41.2 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[87\]](#)

35 / 35 points

35% of total

Clinical experience

No evidence found

0 / 25 points

25% of total

Supporting information

3 matched records backed by 1 linked sources [\[87\]](#)

6.2 / 20 points

20% of total

Speaking and professional activity

No evidence found

0 / 20 points

20% of total

Edmund M. Rusk: Supporting evidence

 Professional profile [\[87\]](#)

Arun S. Mehta, MD, MS

Associate Professor of Medicine

UChicago Medicine Faculty Physicians | Chicago, IL

PROJECT FIT

39.6 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Expertise in minimally invasive diagnosis and treatment of stage lung cancer is relevant to this advisory board brief [\[89\]](#)



Relevant experience

- Has shared expertise through 2 presentations and 1 education program, covering pleural disease and interventional Pulmonology [\[88\]](#) [\[97\]](#) [\[90\]](#)
- Has coauthored 2 congress abstracts [\[95\]](#) [\[98\]](#)
- Scheduled to present at 2 events [\[96\]](#) [\[92\]](#)



Research

- Publications found: 6 [\[94\]](#) [\[100\]](#)



Clinical focus

- Critical Care Medicine [\[89\]](#)
- Interventional Pulmonology [\[89\]](#)



Professional societies

- American Association for Bronchology and Interventional Pulmonology (AABIP) [\[93\]](#)
- American College of Chest Physicians (CHEST) [\[91\]](#)



Congress activity

- Total: 8 (4 congress records + 4 talks/interviews) [\[97\]](#) [\[95\]](#) [\[98\]](#)

Sources [\[88\]](#) Dr. Arun S. Mehta Shares... [\[89\]](#) uchicagomedicine.org [\[90\]](#) Global Tracheostomy... [\[91\]](#) American College of... [\[92\]](#) State of the Art... [\[93\]](#) American Association...

Full references in appendix

Arun S. Mehta: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

39.6 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[89\]](#)

35 / 35 points

35% of total

Clinical experience

No evidence found

0 / 25 points

25% of total

Supporting information

2 matched records backed by 1 linked sources [\[89\]](#)

4.6 / 20 points

20% of total

Speaking and professional activity

No evidence found

0 / 20 points

20% of total

Arun S. Mehta: Supporting evidence

Congress / speaking: Clinical Year in Review · ATS 2026 International Conference · Clinical Year in Review: interventional pulmonary medicine (advanced diagnostic bronchoscopy, pleural disease, BLVR, central airway obstruction) · Presenter (interventional pulmonary medicine segment) [\[97\]](#)

Congress / speaking: Use of the VanGogh System to Assess for Intra-Operative Tissue Adequacy: Initial Experience · 2025 · Poster on dynamic cell imaging of 51 robotic-bronchoscopy peripheral lung biopsies; congress not named on page · Poster co-author (listed last of four authors) [\[95\]](#)

Congress / speaking: Igniting Change in Outpatient Pulmonary Care — Rapid Fire Original Inv · CHEST · 2025 · Abstract: IMPLEMENTATION OF AUTOMATED QUANTITATIVE CT SCAN SCREENING TO IMPROVE QUANTITY AND QUALITY OF REFERRALS FOR BRONCHOSCOPIC LUNG VOLUME REDUCTION; session: Igniting Change in Outpatient Pulmonary Care · Rapid Fire Original Inv · Abstract co-author (not listed as presenter) [\[98\]](#)

Congress / speaking: Tomosynthesis in the Diagnosis of Lung Nodules · State of the Art Lung Nodule Conference 2024: Current Perspectives & Future Directions · Tomosynthesis in the Diagnosis of Lung Nodules (9:05-9:30) · Speaker [\[92\]](#)

Congress / speaking: Virtual Grand Rounds 2026 (hosted by Professor Eric Lim) · 2026-10-30 · Advances in the Management of Recurrent Pleural Effusion · Scheduled speaker (future, 30 October 2026) [\[96\]](#)

Congress / speaking: Global Tracheostomy Collaborative (GTC) Fall Symposium 2025 Program Book · 2025-10-23 · Hands-on tracheostomy course simulation · Hands-on course simulation faculty (not listed as a lecturer) [\[90\]](#)

Congress / speaking: Expert Q&A: COPD and Advanced Emphysema · 2023-05-11 · Latest treatment options for COPD and advanced emphysema (bronchoscopic valve procedures) · Featured expert (discussion participant) [\[99\]](#)

Arun S. Mehta: Supporting evidence - continued

Congress / speaking: Dr. Arun S. Mehta Shares his Experience Using the Ambu aScope 5 HD Single-Use Bronchoscope · 2023-03-22 · aScope 5 Broncho benchtop research lab and use in therapeutic/advanced diagnostic bronchoscopy · Featured speaker (industry video) [\[88\]](#)

Professional profile [\[89\]](#)

Colin J. Wexford, MD, PhD

Thoracic Medical Oncologist

Memorial Sloan Kettering Cancer Center | New York, NY

PROJECT FIT

39.6 /100

Documented alignment



AI-generated illustration



Why this KOL fits

Expertise in or EML4-ALK mutant non-small cell lung cancer). and The treatment of patients with thymic tumors as well as non-small cell lung cancer with specific mutations (EGFR is relevant to this advisory board brief [\[101\]](#)



Relevant experience

- Colin J. Wexford is a board-certified medical oncologist who specializes in treating patients with lung cancer and thymic tumors [\[101\]](#)



Research

- Publications found: 0



Clinical focus

- Clinical trials [\[101\]](#)



Professional societies

- No society affiliations found



Congress activity

- Activities found: 0

Colin J. Wexford: Project fit

Each category adds points to the total. More points mean a closer match to this project's needs.

39.6 / 100

Match to the brief

How closely the profile matches the topics and requirements in your brief [\[101\]](#)

35 / 35 points

35% of total

Clinical experience

No evidence found

0 / 25 points

25% of total

Supporting information

2 matched records backed by 1 linked sources [\[101\]](#)

4.6 / 20 points

20% of total

Speaking and professional activity

No evidence found

0 / 20 points

20% of total

Colin J. Wexford: Supporting evidence

 Professional profile [\[101\]](#)

Public professional evidence

Source 1: nyulangone.org · Accessed 2026-10-06

Original reference: <https://nyulangone.org/doctors/1356638894/adrian-k-vasquez>

Source 2: [Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases](#) · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/42098425>

Source 3: [SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC](#) · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/41940628>

Source 4: [2025 ASCO Annual Meeting](#) · Accessed 2026-10-06

Original reference: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8620

Source 5: [IASLC 2026 World Conference on Lung Cancer \(WCLC 2026\)](#) · Accessed 2026-10-06

Original reference: <https://cor2ed.com/lung-connect/programmes/her2-mutant-nsclc-wclc-2026/>

Source 6: [Highlights from the American Society of Clinical Oncology \(ASCO\) 2026 Annual Meeting](#) · Accessed 2026-10-06

Original reference: [https://www.cancercare.org/services/workshops/11853-highlights-from-the-american-society-of-clinical-oncology-\(asco\)-2026-annual-meeting](https://www.cancercare.org/services/workshops/11853-highlights-from-the-american-society-of-clinical-oncology-(asco)-2026-annual-meeting)

Source 7: [Breaking Down Advancements in Prostate Cancer Care](#) · Accessed 2026-10-06

Original reference: <https://www.curetoday.com/view/breaking-down-advancements-in-prostate-cancer-care>

Public professional evidence - continued

Source 8: Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

· Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/41820335>

Source 9: Experts Highlight Notable Advances in Colorectal Cancer at 2025 ESMO · Accessed 2026-10-06

Original reference: <https://www.curetoday.com/view/experts-highlight-notable-advances-in-colorectal-cancer-at-2025-esmo>

Source 10: 2026 ASCO Annual Meeting · Accessed 2026-10-06

Original reference: <https://physicianfocus.nyulangone.org/wp-content/uploads/2026/05/ASCO-Presentations-5.31.26.pdf>

Source 11: First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/41985129>

Source 12: Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States. · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/40320171>

Source 13: Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability. · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/41932250>

Source 14: American Society of Clinical Oncology (ASCO) · Accessed 2026-10-06

Original reference: <https://www.doximity.com/pub/adrian-vasquez-md>

Public professional evidence - continued

[Source 15: IASLC 2025 World Conference on Lung Cancer \(WCLC 2025\)](#) · Accessed 2026-10-06

Original reference: <https://www.curetoday.com/conference/iaslc-world-conference-on-lung-cancer>

[Source 16: Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study.](#) ·

Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42489696/>

[Source 17: profiles.hopkinsmedicine.org](#) · Accessed 2026-10-06

Original reference: <https://profiles.hopkinsmedicine.org/provider/nadia-a-brenner/2701157>

[Source 18: Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR \(C797X\) Mutation Following First-Line Osimertinib: ORCHARD.](#) · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42440354/>

[Source 19: 2024 KRAS Kickers Hope Filled Summit](#) · Accessed 2026-10-06

Original reference: <https://www.youtube.com/watch?v=5uKlt-SwfnA>

[Source 20: IASLC | ASCO 2025 North America Conference on Lung Cancer \(NACLC 2025\)](#) · Accessed 2026-10-06

Original reference: <https://www.ilcn.org/looking-ahead-to-the-iaslc-asco-2025-north-america-conference-on-lung-cancer/>

Public professional evidence - continued

Source 21: Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42348812/>

Source 22: Mastering Fellowship Interview Season: What Programs Value and How Applicants Can Stand Out · Accessed 2026-10-06

Original reference: <https://connection.asco.org/do/mastering-fellowship-interview-season-programs-value-and-applicants-can-stand-out>

Source 23: 2026 UVA Medical Oncology Update · Accessed 2026-10-06

Original reference: <https://uva.cloud-cme.com/default.aspx?P=0&EID=31780>

Source 24: Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/41780641/>

Source 25: Educational Priorities in Oncologic Critical Care: A Modified Delphi Study. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42836669/>

Source 26: Preview: IASLC | ASCO 2025 North American Conference on Lung Cancer (podcast) · Accessed 2026-10-06

Original reference: <https://education.iaslc.org/Listing/Preview-IASLC-ASCO-2025-North-American-Conference-on-Lung-Cancer-15625>

Source 27: IASLC North America Conference on Lung Cancer 2026 (NACLC 2026) · Accessed 2026-10-06

Original reference: <https://conferences.iaslc.org/e/naclc>

Public professional evidence - continued

Source 28: AACR Annual Meeting 2026 · Accessed 2026-10-06

Original reference: https://aacrjournals.org/cancerres/article/86/7_Supplement/110/775848

Source 29: Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer. ·

Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42001597/>

Source 30: 2026 ASCO Annual Meeting · Accessed 2026-10-06

Original reference: https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.8517

Source 31: profiles.hopkinsmedicine.org · Accessed 2026-10-06

Original reference: <https://profiles.hopkinsmedicine.org/provider/marta-c-delaney/2701814>

Source 32: Comparing Osimertinib-Based Frontline Combination Regimens in EGFR-Mutant NSCLC · Accessed 2026-10-06

Original reference: <https://www.onclive.com/authors/marta-delaney-md>

Source 33: 2026 ASCO Annual Meeting · Accessed 2026-10-06

Original reference: <https://oncodaily.com/voices/lung-cancer-509064>

Source 34: First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/38975613/>

Public professional evidence - continued

Source 35: Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical EGFR Mutation: A Molecular Tumor Board Discussion. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42385104/>

Source 36: Immunotherapy in Action: Multidisciplinary Strategies to Improve Care in Advanced/Metastatic NSCLC · Accessed 2026-10-06

Original reference: <https://primeinc.org/faculty-biography/marta-c-delaney-md-4882>

Source 37: Unveiling the Latest Updates in EGFR-Mutated Advanced NSCLC · Accessed 2026-10-06

Original reference: <https://www.medscape.org/viewarticle/unveiling-latest-updates-egfr-mutated-advanced-nsclc-2025a1000595>

Source 38: A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/39998620/>

Source 39: Real-World Association Between Up-Front Next-Generation Sequencing and Overall Survival in Advanced Non-Small Cell Lung Cancer in the United States. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42804730/>

Source 40: Future Directions Beyond Osimertinib in EGFR-Mutant NSCLC · Accessed 2026-10-06

Original reference: <https://www.onclive.com/view/future-directions-beyond-osimertinib-in-egfr-mutant-nsclc>

Public professional evidence - continued

Source 41: IASLC 2025 World Conference on Lung Cancer (WCLC 2025) · Accessed 2026-10-06

Original reference: <https://ascopost.com/videos/iaslc-wclc-2025/egfr-mutated-nsclc-subcutaneous-amivantamab-plus-lazertinib/>

Source 42: 2025 American Society of Clinical Oncology (ASCO) Annual Meeting · Accessed 2026-10-06

Original reference:

<https://investors.nuvalent.com/2025-04-23-Nuvalent-to-Present-Trial-in-Progress-Posters-for-the-ALKAZAR-Trial-of-Neladalkib-and-HEROEX-1-Trial-of-NVL-330-at-the-2025-American-Society-of-Clinical-Oncology-Annual-Meeting>

Source 43: First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/41985129/>

Source 44: Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42207168/>

Source 45: fredhutch.org · Accessed 2026-10-06

Original reference: <https://www.fredhutch.org/en/people/b/irene-halvorsen.html>

Source 46: Winter Lung 2026 · Accessed 2026-10-06

Original reference: <https://registration.gotoper.com/winter-lung-2026/agenda/speakers/3827851>

Public professional evidence - continued

Source 47: BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/42126003/>

Source 48: A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs · Accessed 2026-10-06

Original reference:

<https://registration.gotoper.com/a-new-era-of-targeted-therapy-for-advanced-nsclc-exploring-future-directions-for-bispecific-antibodies-and-adcs/agenda/speakers/3762503>

Source 49: Seattle Lung Cancer Conference · Accessed 2026-10-06

Original reference: <https://binaytara.org/news/education/2025-seattle-lung-cancer-conference-highlights>

Source 50: Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/41537704/>

Source 51: Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/41886723/>

Source 52: 2026 Lung Cancer Patient Empowerment Webinar · Accessed 2026-10-06

Original reference: <https://www.eventbrite.com/e/2026-lung-cancer-patient-empowerment-webinar-tickets-1995038461744>

Public professional evidence - continued

Source 53: Masters in Thoracic Oncology Summit · Accessed 2026-10-06

Original reference: <https://www.iaslc.org/sites/default/files/2024-09/2024%20MaTOS%20Agenda%208.23.24lg-cc.pdf>

Source 54: Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/41639379/>

Source 55: Dr Halvorsen on the Clinical Utility of Zongertinib in Previously Treated HER2-Mutant NSCLC · Accessed 2026-10-06

Original reference: <https://www.onclive.com/view/dr-halvorsen-on-the-clinical-utility-of-zongertinib-in-previously-treated-her2-mutant-nsclc>

Source 56: education.musc.edu · Accessed 2026-10-06

Original reference: <https://education.musc.edu/muscapps/facultydirectory/Castellan-Roy>

Source 57: Evaluation Of An Artificial Intelligence-Generated Brock Score To Determine Malignancy Risk In Screen Detected Nodules · Accessed 2026-10-06

Original reference: <https://www.ovid.com/journals/chst/pdf/10.1016/j.chest.2025.07.2676~evaluation-of-an-artificial-intelligence-generated-brock>

Source 58: Deep Breaths: Updates from CHEST · Accessed 2026-10-06

Original reference: <https://reachmd.com/programs/deep-breaths-updates-chest/understanding-extensive-stage-small-cell-lung-cancer-advancements-and-ongoing-challenges/32973/>

Public professional evidence - continued

Source 59: Evaluation of an artificial intelligence generated Brock score to determine malignancy risk of screen-detected pulmonary nodules. · Accessed 2026-10-06

Original reference: <https://pmc.ncbi.nlm.nih.gov/articles/PMC13235500/>

Source 60: ATS 2024 International Conference - President's Symposium · Accessed 2026-10-06

Original reference: <https://www.atsconferencenews.org/presidents-symposium-details-tremendous-progress-bright-future-for-lung-cancer-care/>

Source 61: Health Focus · Accessed 2026-10-06

Original reference: <https://www.southcarolinapublicradio.org/show/health-focus/2026-08-17/research-regarding-advanced-lung-cancer-patients-and-treatment>

Source 62: CHEST Journal Podcast · Accessed 2026-10-06

Original reference:

<https://prodweb02.chestnet.org/guidelines-and-topic-collections/media-galleries/chest-journal-podcast/outcomes-from-more-than-1-million-people-screened-for-lung-cancer-with-low-dose-ct-imaging>

Source 63: A pulmonary inferno: the triad of interstitial abnormalities, emphysema, and lung cancer. · Accessed 2026-10-06

Original reference: <https://pmc.ncbi.nlm.nih.gov/articles/PMC13037568/>

Source 64: American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) · Accessed 2026-10-06

Original reference: <https://nlcrt.org/people/roy-a-castellan-md-ms/>

Public professional evidence - continued

[Source 65: Biodesix ATS 2026 presentations \(ATS 2026 International Conference\)](#) · Accessed 2026-10-06

Original reference: <https://investors.biodesix.com/news-releases/news-release-details/biodesix-announces-ats-2026-presentations-providing-real-world>

[Source 66: Pulmonary Nodules.](#) · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/42685318>

[Source 67: The United States' Early Experience With Lung Cancer Screening-Creation of a National Data Linkage: A Brief Report.](#) · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/40420868>

[Source 68: IASLC 2024 World Conference on Lung Cancer](#) · Accessed 2026-10-06

Original reference: <https://wclc.iaslc.org/archive-wclc-2024/>

[Source 69: American College of Chest Physicians \(CHEST\)](#) · Accessed 2026-10-06

Original reference: <https://www.accc-cancer.org/authors/castellan>

[Source 70: The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.](#) · Accessed 2026-10-06

Original reference: <https://doi.org/10.1002/cncr.70384>

[Source 71: Navigating the Path Ahead: Preparing for Life Beyond IP Fellowship \(2026\)](#) · Accessed 2026-10-06

Original reference: <https://www.aabronchology.org/navigating-the-path-ahead-preparing-for-life-beyond-ip-fellowship-2026>

Public professional evidence - continued

Source 72: [uchicagomedicine.org](https://www.uchicagomedicine.org) · Accessed 2026-10-06

Original reference: <https://www.uchicagomedicine.org/find-a-physician/physician/dorian-petrescu>

Source 73: American Association for Bronchology and Interventional Pulmonology (AABIP) · Accessed 2026-10-06

Original reference: <https://aabipconference.com/conference-committees/>

Source 74: A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy. · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/42392503>

Source 75: Procedure Patterns and Survival in Advanced Non-Small Cell Lung Cancer With Malignant Airway Obstruction: A Surveillance, Epidemiology, and End Results Medicare Analysis. · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/40882700>

Source 76: Response to 'A Mechanistic and Morphologic Approach to Managing Benign Central Airway Obstruction'. · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/41402985>

Source 77: AABIP 2025 Annual Conference · Accessed 2026-10-06

Original reference: <https://aabip2025.kenes.com/aabip-2025-workshop-and-ask-the-expert-description/>

Source 78: WABIP Two-Day Global Webinar (World Association for Bronchology and Interventional Pulmonology) · Accessed 2026-10-06

Original reference: https://cdn.wabip.com/wp-content/downloads/newsletter/WABIP_Newsletter_2025_Issue3.pdf

Public professional evidence - continued

Source 79: Atypical Histology in Pulmonary Biopsies Obtained Using Robotic-Assisted Bronchoscopy: Natural History and Clinical Practice. · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/41571025>

Source 80: 4th Annual State of the Art Lung Nodule Symposium 2025: Current Perspectives & Future Directions · Accessed 2026-10-06

Original reference: <https://ce.advocatehealth.org/content/4th-annual-state-art-lung-nodule-symposium-2025-current-perspectives-future-directions>

Source 81: Robotic Bronchoscopy for Multiple Pulmonary Nodules: Mitigating the Oversimplification Bias. · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/42544772>

Source 82: American College of Chest Physicians (CHEST) · Accessed 2026-10-06

Original reference: <https://www.chestnet.org/membership-and-community/leadership/committees>

Source 83: Clamping the Chest Tube: Always Or Never? - Beware the Flaws of Binary Thinking! · Accessed 2026-10-06

Original reference: <https://europepmc.org/article/MED/41813299>

Source 84: 2025 IP Fellows Advanced Course · Accessed 2026-10-06

Original reference: https://www.aabronchology.org/index.php?servId=11019&showall=1&option=com_content&id=440

Source 85: Tips for a Successful IP Training 2025 · Accessed 2026-10-06

Original reference: <https://aabip.memberclicks.net/tips-for-a-successful-ip-training-2025>

Public professional evidence - continued

Source 86: AABIP 2026 Annual Conference · Accessed 2026-10-06

Original reference: <https://aabipconference2027.kgstaging.com/>

Source 87: mskcc.org · Accessed 2026-10-06

Original reference: <https://www.mskcc.org/cancer-care/doctors/edmund-m-rusk>

Source 88: Dr. Arun S. Mehta Shares his Experience Using the Ambu aScope 5 HD Single-Use Bronchoscope · Accessed 2026-10-06

Original reference: <https://video.ambuusa.com/dr-arun-mehta-shares-his-experience>

Source 89: uchicagomedicine.org · Accessed 2026-10-06

Original reference: <https://www.uchicagomedicine.org/find-a-physician/physician/arun-mehta>

Source 90: Global Tracheostomy Collaborative (GTC) Fall Symposium 2025 Program Book · Accessed 2026-10-06

Original reference: https://assets.nationbuilder.com/gtc/pages/476/attachments/original/1761166876/GTC_FallSymp25_Program_Agenda_v12.pdf?1761166876

Source 91: American College of Chest Physicians (CHEST) · Accessed 2026-10-06

Original reference: <https://www.chestnet.org/learning-and-events/events/chest-annual-meeting/awards>

Source 92: State of the Art Lung Nodule Conference 2024: Current Perspectives & Future Directions · Accessed 2026-10-06

Original reference: <https://www.noahmed.com/hubfs/Events/2024/Flyer%20Final%20Lung%20Nodule%20Symposium%2011-22-24.pdf?hsLang=en>

Public professional evidence - continued

Source 93: American Association for Bronchology and Interventional Pulmonology (AABIP) · Accessed 2026-10-06

Original reference: <https://www.aabronchology.org/committees-sub>

Source 94: Immune biomarkers in CTD-ILD: Promise, practicality and the path to validation. · Accessed 2026-10-06

Original reference: <https://pubmed.ncbi.nlm.nih.gov/?term=Mehta+A%5Bau%5D+AND+Chicago%5Bad%5D&sort=date&size=50>

Source 95: Use of the VanGogh System to Assess for Intra-Operative Tissue Adequacy: Initial Experience · Accessed 2026-10-06

Original reference: <https://www.celltivity.com/resources/use-of-the-vangogh-system-to-assess-for-intra-operative-tissue-adequacy-initial-experience>

Source 96: Virtual Grand Rounds 2026 (hosted by Professor Eric Lim) · Accessed 2026-10-06

Original reference: <https://www.drericlim.com/brompton-grand-rounds>

Source 97: ATS 2026 International Conference · Accessed 2026-10-06

Original reference:

<https://www.atsconferencenews.org/final-clinical-year-in-review-session-shares-state-of-the-art-science-in-copd-interventional-pulmonary-medicine-medical-education-and-lung-cancer/>

Source 98: CHEST · Accessed 2026-10-06

Original reference: [https://journal.chestnet.org/article/S0012-3692\(25\)03377-X/pdf](https://journal.chestnet.org/article/S0012-3692(25)03377-X/pdf)

Source 99: Expert Q&A: COPD and Advanced Emphysema · Accessed 2026-10-06

Original reference: <https://www.youtube.com/watch?v=PrE6DnQkjdk>

Public professional evidence - continued

Source 100: Forty years between contralateral bullectomies for giant pulmonary bullae: a case report. · Accessed 2026-10-06

Original reference: <https://medicine.uchicago.edu/faculty/arun-mehta-md/publications>

Source 101: mskcc.org · Accessed 2026-10-06

Original reference: <https://www.mskcc.org/cancer-care/doctors/colin-j-wexford>

What a perfect project fit looks like

A fully documented match earns all the points below. Each example shows one way to reach full marks in that category.		100 / 100
Match to the brief	Matches every topic used to score the brief	35 points
Clinical experience	Relevant clinical work and disease-specific research are supported by sources	25 points
Supporting information	Relevant information is backed by a broad set of linked sources	20 points
Speaking and professional activity	Relevant speaking and professional contributions are supported by sources	20 points

How partial points work

A 60% match earns 60% of the points available in that category. Full marks mean all scored topics match the profile; missing matches can reflect how the profile is worded.